Peng Y, Xu R-H, Mei J-M, Li X-P, Yan D, Kung H-F, Phang J M
Metabolism and Cancer Susceptibility Section, Basic Research Laboratory, NCI-FCRDC, National Institutes of Health, Frederick, MD 21702-1201, USA.
Neuroscience. 2002;109(4):657-64. doi: 10.1016/s0306-4522(01)00526-7.
The transcription factor, activator protein 1 (AP-1) complexes (c-Jun and c-Fos heterodimers) has been shown to interact with transforming growth factor beta signaling in mammalian cells and Drosophila embryo. Here we show that c-Jun alone is involved in the anti-neuralizing activity of bone morphogenetic protein 4, a transforming growth factor beta superfamily member, in Xenopus neurogenesis. Co-injection of mRNAs encoding c-jun and a dominant negative bone morphogenetic protein receptor completely inhibits dominant negative bone morphogenetic protein receptor-induced neuralization and reverses the epidermal fate in the animal cap. Surprisingly, a dominant negative c-Jun does not induce neural tissue in the animal cap, but it synergizes with dominant negative bone morphogenetic protein receptor for neural induction. Temporal analysis using a dexamethasone-inducible c-Jun shows that exogenous c-Jun activity must be turned on before or at stage 11 to fulfill the anti-neuralizing effect. Neural inhibition by c-Jun does not occur until stage 13 suggesting that c-Jun probably acts by suppressing neural maintenance rather than neural initiation. This is also supported by the fact that c-Jun does not inhibit expression of the neural-initializing gene Zic-r1 but the neural cofactor Sox2, and that ectopic expression of Sox2 attenuates the anti-neuralizing effect of c-Jun. Finally, we display that the c-Jun effect is enhanced by an auto-regulatory loop between c-Jun and bone morphogenetic protein. These studies suggest that c-Jun/AP-1 is a converging point in both the fibroblast growth factor and transforming growth factor beta signaling pathways. Based on our findings, we propose that c-Jun synergizes with bone morphogenetic protein 4 signaling to inhibit neural development in Xenopus ectoderm.
转录因子激活蛋白1(AP-1)复合物(c-Jun和c-Fos异源二聚体)已被证明在哺乳动物细胞和果蝇胚胎中与转化生长因子β信号传导相互作用。在此我们表明,在非洲爪蟾神经发生过程中,单独的c-Jun参与了骨形态发生蛋白4(一种转化生长因子β超家族成员)的抗神经化活性。共注射编码c-jun的mRNA和显性负性骨形态发生蛋白受体可完全抑制显性负性骨形态发生蛋白受体诱导的神经化,并逆转动物帽中的表皮命运。令人惊讶的是,显性负性c-Jun不会在动物帽中诱导神经组织,但它与显性负性骨形态发生蛋白受体协同作用以进行神经诱导。使用地塞米松诱导型c-Jun的时间分析表明,外源性c-Jun活性必须在第11阶段之前或之时开启,以实现抗神经化作用。c-Jun对神经的抑制直到第13阶段才发生,这表明c-Jun可能通过抑制神经维持而非神经起始发挥作用。这也得到以下事实的支持:c-Jun不抑制神经起始基因Zic-r1的表达,但抑制神经辅助因子Sox2的表达,并且Sox2的异位表达减弱了c-Jun的抗神经化作用。最后,我们显示c-Jun和骨形态发生蛋白之间的自调节环增强了c-Jun的作用。这些研究表明,c-Jun/AP-1是成纤维细胞生长因子和转化生长因子β信号通路的一个汇聚点。基于我们的发现,我们提出c-Jun与骨形态发生蛋白4信号协同作用以抑制非洲爪蟾外胚层的神经发育。